246 related articles for article (PubMed ID: 27044878)
1. Selection of individuals for genetic testing for familial hypercholesterolaemia: development and external validation of a prediction model for the presence of a mutation causing familial hypercholesterolaemia.
Besseling J; Reitsma JB; Gaudet D; Brisson D; Kastelein JJ; Hovingh GK; Hutten BA
Eur Heart J; 2017 Feb; 38(8):565-573. PubMed ID: 27044878
[TBL] [Abstract][Full Text] [Related]
2. Familial Hypercholesterolaemia in the Era of Genetic Testing.
Hughes DP; Viljoen A; Wierzbicki AS
Curr Cardiol Rep; 2016 May; 18(5):42. PubMed ID: 27002618
[TBL] [Abstract][Full Text] [Related]
3. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies.
Nherera L; Marks D; Minhas R; Thorogood M; Humphries SE
Heart; 2011 Jul; 97(14):1175-81. PubMed ID: 21685482
[TBL] [Abstract][Full Text] [Related]
4. Improving identification of familial hypercholesterolaemia in primary care: derivation and validation of the familial hypercholesterolaemia case ascertainment tool (FAMCAT).
Weng SF; Kai J; Andrew Neil H; Humphries SE; Qureshi N
Atherosclerosis; 2015 Feb; 238(2):336-43. PubMed ID: 25555265
[TBL] [Abstract][Full Text] [Related]
5. Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia.
Miltiadous G; Xenophontos S; Bairaktari E; Ganotakis M; Cariolou M; Elisaf M
Pharmacogenet Genomics; 2005 Apr; 15(4):219-25. PubMed ID: 15864114
[TBL] [Abstract][Full Text] [Related]
6. A Belgian consensus strategy to identify familial hypercholesterolaemia in the coronary care unit and its subsequent cascade screening and treatment: BEL-FaHST (The BELgium Familial Hypercholesterolaemia STrategy).
Descamps OS; Van Caenegem O; Hermans MP; Balligand JL; Beauloye C; Bondue A; Carlier S; Castermans E; Chenot F; Claeys M; De Block C; de Leener A; De Meester A; Demeure F; De Raedt H; Desmet W; Elegeert I; Guillaume M; Hoffer E; Kacenelenbogen R; Lancellotti P; Langlois M; Leone A; Mertens A; Paquot N; Vanakker O; Vanoverschelde JL; Verhaegen A; Vermeersch P; Wallemacq C; Rietzschel E;
Atherosclerosis; 2018 Oct; 277():369-376. PubMed ID: 30270073
[TBL] [Abstract][Full Text] [Related]
7. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia.
Heath KE; Gudnason V; Humphries SE; Seed M
Atherosclerosis; 1999 Mar; 143(1):41-54. PubMed ID: 10208479
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and treatment of familial hypercholesterolaemia.
Hovingh GK; Davidson MH; Kastelein JJ; O'Connor AM
Eur Heart J; 2013 Apr; 34(13):962-71. PubMed ID: 23416791
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales.
Haralambos K; Whatley SD; Edwards R; Gingell R; Townsend D; Ashfield-Watt P; Lansberg P; Datta DB; McDowell IF
Atherosclerosis; 2015 May; 240(1):190-6. PubMed ID: 25797312
[TBL] [Abstract][Full Text] [Related]
10. Suboptimal consideration and management of potential familial hypercholesterolaemia in patients with suspected premature coronary artery disease.
Yudi M; Omera L; McCubbery N; Dick S; Jayasinghe R; Hamilton-Craig I
Singapore Med J; 2012 Mar; 53(3):174-8. PubMed ID: 22434290
[TBL] [Abstract][Full Text] [Related]
11. Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia.
Rubba P; Gentile M; Marotta G; Iannuzzi A; Sodano M; De Simone B; Jossa F; Iannuzzo G; Giacobbe C; Di Taranto MD; Fortunato G
Eur J Prev Cardiol; 2017 Jul; 24(10):1051-1059. PubMed ID: 28353356
[TBL] [Abstract][Full Text] [Related]
12. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.
Wiegman A; Gidding SS; Watts GF; Chapman MJ; Ginsberg HN; Cuchel M; Ose L; Averna M; Boileau C; Borén J; Bruckert E; Catapano AL; Defesche JC; Descamps OS; Hegele RA; Hovingh GK; Humphries SE; Kovanen PT; Kuivenhoven JA; Masana L; Nordestgaard BG; Pajukanta P; Parhofer KG; Raal FJ; Ray KK; Santos RD; Stalenhoef AF; Steinhagen-Thiessen E; Stroes ES; Taskinen MR; Tybjærg-Hansen A; Wiklund O;
Eur Heart J; 2015 Sep; 36(36):2425-37. PubMed ID: 26009596
[TBL] [Abstract][Full Text] [Related]
13. Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia: Insights From the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study).
Pérez de Isla L; Alonso R; Mata N; Saltijeral A; Muñiz O; Rubio-Marin P; Diaz-Diaz JL; Fuentes F; de Andrés R; Zambón D; Galiana J; Piedecausa M; Aguado R; Mosquera D; Vidal JI; Ruiz E; Manjón L; Mauri M; Padró T; Miramontes JP; Mata P;
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):2004-10. PubMed ID: 27444203
[TBL] [Abstract][Full Text] [Related]
14. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.
deGoma EM; Ahmad ZS; O'Brien EC; Kindt I; Shrader P; Newman CB; Pokharel Y; Baum SJ; Hemphill LC; Hudgins LC; Ahmed CD; Gidding SS; Duffy D; Neal W; Wilemon K; Roe MT; Rader DJ; Ballantyne CM; Linton MF; Duell PB; Shapiro MD; Moriarty PM; Knowles JW
Circ Cardiovasc Genet; 2016 Jun; 9(3):240-9. PubMed ID: 27013694
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: an Australian experience.
Bell DA; Pang J; Burrows S; Bates TR; van Bockxmeer FM; Hooper AJ; O'Leary P; Burnett JR; Watts GF
Atherosclerosis; 2015 Mar; 239(1):93-100. PubMed ID: 25585028
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes.
Nanchen D; Gencer B; Auer R; Räber L; Stefanini GG; Klingenberg R; Schmied CM; Cornuz J; Muller O; Vogt P; Jüni P; Matter CM; Windecker S; Lüscher TF; Mach F; Rodondi N
Eur Heart J; 2015 Sep; 36(36):2438-45. PubMed ID: 26142466
[TBL] [Abstract][Full Text] [Related]
17. Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217.
Benn M; Watts GF; Tybjærg-Hansen A; Nordestgaard BG
Eur Heart J; 2016 May; 37(17):1384-94. PubMed ID: 26908947
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular disease in familial hypercholesterolemia: Validation and refinement of the Montreal-FH-SCORE.
Paquette M; Brisson D; Dufour R; Khoury É; Gaudet D; Baass A
J Clin Lipidol; 2017; 11(5):1161-1167.e3. PubMed ID: 28801029
[TBL] [Abstract][Full Text] [Related]
19. New Horizons in the Pathogenesis, Pathophysiology and Treatment of Familial Hypercholesterolaemia.
Viigimaa M; Heinsar S; Lovic D; Katsimardou A; Piperidou A; Duishvili D
Curr Pharm Des; 2018; 24(31):3599-3604. PubMed ID: 30306860
[TBL] [Abstract][Full Text] [Related]
20. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).
EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
Lancet; 2021 Nov; 398(10312):1713-1725. PubMed ID: 34506743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
